Lexicon Pharmaceuticals, Inc.
LXRXNASDAQHealthcare● Active
$1.90
$-0.01(-0.28%)
Market Cap$846060121
P/E Ratio—
52W High$2.53
52W Low$0.64
Lexicon Pharmaceuticals, Inc. (LXRX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
LXRX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.00
Est. -$0.04 · +93.5%
Revenue
$0.02B
Est. $0.01B · +115.5%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 6-Quarter EPS Beat Streak
LXRX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | -$0.06 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.04 | -$0.00 | +93.5% | $0.02B | $0.01B | +115.5% |
| ▲ Q1 FY2026 | Mar 5, 2026 | -$0.07 | -$0.04 | +42.9% | $0.01B | $0.00B | +74.8% |
| ▲ Q4 FY2025 | Nov 6, 2025 | -$0.07 | -$0.04 | +42.9% | $0.01B | $0.00B | +351.4% |
| ▲ Q3 FY2025 | Aug 6, 2025 | -$0.08 | $0.01 | +112.5% | $0.03B | $0.01B | +396.7% |
| ▲ Q2 FY2025 | May 13, 2025 | -$0.10 | -$0.07 | +30.0% | $0.00B | $0.00B | -3.4% |
| ▲ Q1 FY2025 | Mar 6, 2025 | -$0.11 | -$0.09 | +18.2% | $0.03B | $0.00B | +842.6% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -$0.17 | -$0.18 | -5.9% | $0.00B | $0.01B | -73.0% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
-$0.06
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.00
EPS Est.
-$0.04
EPS Surpr.
+93.5%
Revenue
$0.02B
Q1 FY2026
Mar 5, 2026Beat
EPS Actual
-$0.04
EPS Est.
-$0.07
EPS Surpr.
+42.9%
Revenue
$0.01B
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$0.04
EPS Est.
-$0.07
EPS Surpr.
+42.9%
Revenue
$0.01B
Q3 FY2025
Aug 6, 2025Beat
EPS Actual
$0.01
EPS Est.
-$0.08
EPS Surpr.
+112.5%
Revenue
$0.03B
Q2 FY2025
May 13, 2025Beat
EPS Actual
-$0.07
EPS Est.
-$0.10
EPS Surpr.
+30.0%
Revenue
$0.00B
Q1 FY2025
Mar 6, 2025Beat
EPS Actual
-$0.09
EPS Est.
-$0.11
EPS Surpr.
+18.2%
Revenue
$0.03B
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
-$0.18
EPS Est.
-$0.17
EPS Surpr.
-5.9%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q3 FY2027 | $-0.05 | $-0.05 | $-0.05 | 1 |
| Q2 FY2027 | $-0.06 | $-0.06 | $-0.06 | 1 |
| Q1 FY2027 | $-0.06 | $-0.06 | $-0.06 | 1 |
| Q4 FY2026 | $-0.05 | $-0.05 | $-0.05 | 1 |
| Q3 FY2026 | $-0.07 | $-0.06 | $-0.05 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +93.5% | $1.60 | $1.68 | +5.00% |
| ▲ Q1 FY2026 | Mar 5, 2026 | +42.9% | $1.63 | $1.64 | +0.61% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +42.9% | $1.38 | $1.43 | +3.62% |
| ▲ Q3 FY2025 | Aug 6, 2025 | +112.5% | $1.05 | $1.15 | +9.52% |
| ▲ Q2 FY2025 | May 13, 2025 | +30.0% | $0.67 | $0.63 | -6.51% |
| ▲ Q1 FY2025 | Mar 6, 2025 | +18.2% | $0.34 | $0.37 | +9.43% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -5.9% | $1.27 | $1.19 | -6.30% |
| ▲ Q3 FY2024 | Aug 1, 2024 | +5.6% | $2.25 | $2.02 | -10.22% |
Q2 FY2026+5.00%
Report Date
May 7, 2026
EPS Beat/Miss
+93.5%
Price Before
$1.60
Price After
$1.68
Q1 FY2026+0.61%
Report Date
Mar 5, 2026
EPS Beat/Miss
+42.9%
Price Before
$1.63
Price After
$1.64
Q4 FY2025+3.62%
Report Date
Nov 6, 2025
EPS Beat/Miss
+42.9%
Price Before
$1.38
Price After
$1.43
Q3 FY2025+9.52%
Report Date
Aug 6, 2025
EPS Beat/Miss
+112.5%
Price Before
$1.05
Price After
$1.15
Q2 FY2025-6.51%
Report Date
May 13, 2025
EPS Beat/Miss
+30.0%
Price Before
$0.67
Price After
$0.63
Q1 FY2025+9.43%
Report Date
Mar 6, 2025
EPS Beat/Miss
+18.2%
Price Before
$0.34
Price After
$0.37
Q4 FY2024-6.30%
Report Date
Nov 12, 2024
EPS Beat/Miss
-5.9%
Price Before
$1.27
Price After
$1.19
Q3 FY2024-10.22%
Report Date
Aug 1, 2024
EPS Beat/Miss
+5.6%
Price Before
$2.25
Price After
$2.02
Avg Beat Reaction+1.64%
Avg Miss Reaction-6.30%
Beat Rate7 / 8 quarters
Largest Move-10.22% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: LXRX ends December
Lexicon Pharmaceuticals, Inc. (LXRX) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.00 — beating the analyst consensus of $-0.04 by +93.5%. LXRX has beaten EPS estimates for 6 consecutive quarters. The next LXRX earnings date is expected around September 1, 2026.
Each quarter, investors track LXRX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. LXRX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
LXRX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
LXRX earnings · 5 questionsLexicon Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. LXRX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; LXRX historically reports after market close (AMC).
LXRX earnings datewhen is LXRX earningsLXRX next earnings datewhen does LXRX report earningsLXRX earnings calendar
▸ Source: FMP · Lexicon Pharmaceuticals, Inc. SEC filings · US GAAP · Lexicon Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026